Other OTC - Delayed Quote USD

Alzex Neuropharma Inc. (TRRI)

0.2470 +0.0970 (+64.67%)
At close: April 26 at 3:57 PM EDT

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Robert Rosner Chief Executive Officer, President and Director -- -- 1965

Alzex Neuropharma Inc.

8275 S. Eastern Avenue
Suite 200-168
Las Vegas, NV 89123
United States
310-435-0435 https://www.trinresinc.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Alzex Neuropharma Inc., a development stage biopharmaceutical company, engages in developing therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company was formerly known as Trinity Resources Inc. and changed its name to Alzex Neuropharma Inc. in December 2022. The company was incorporated in 1971 and is headquartered in Las Vegas, Nevada.

Corporate Governance

Alzex Neuropharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

GSTC GlobeStar Therapeutics Corporation
0.0009
0.00%
 
MLECW Moolec Science SA
0.0501
-16.36%
 
KPRX Kiora Pharmaceuticals, Inc.
0.4700
-2.08%
 
GLSI Greenwich LifeSciences, Inc.
13.12
+6.32%
 
PHIO Phio Pharmaceuticals Corp.
0.6820
+1.34%
 
VERU Veru Inc.
1.2700
+4.96%
 
ATOS Atossa Therapeutics, Inc.
1.5300
+0.66%
 
BDRX Biodexa Pharmaceuticals Plc
1.3000
+80.56%
 
MLEC Moolec Science SA
1.4500
+2.11%